Seres Therapeutics. has filed a patent for bacterial compositions designed to treat complications in immune-suppressed patients, such as infections and GvHD. The composition includes specific bacteria capable of reducing VRE and CRE carriage, protecting the epithelial barrier, and reducing inflammation. GlobalData’s report on Seres Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Seres Therapeutics, Microbiota restoration therapy was a key innovation area identified from patents. Seres Therapeutics's grant share as of January 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Bacterial composition for treating complications in immune suppression
A patent application (Publication Number: US20240000859A1) discloses a composition comprising a purified population of bacteria with specific characteristics. The bacteria in the composition are capable of reducing VRE and CRE carriage, protecting the epithelial barrier from inflammatory damage, and reducing inflammation in the GI tract. The composition includes various bacteria such as Eubacterium maltosivorans, Clostridium aldenense, and Akkermansia muciniphila, among others. The composition aims to decrease infections caused by ESKAPE pathogens, Enterococcus species, Enterobacteriaceae species, and antibiotic-resistant bacteria. Additionally, the composition is designed to improve epithelial barrier integrity, reduce inflammation, and decrease mortality due to invasive infections in subjects undergoing transplantation. The composition also modulates biological activities such as short-chain fatty acid production, tryptophan metabolite production, and Wnt activation, among others.
Furthermore, the patent application describes methods for treating diseases associated with immune responses, reducing the risk of infections, preventing rejection in transplantation, and improving overall survival in subjects. The methods involve administering the disclosed composition to subjects in need. The composition is also effective in reducing the risk of complications related to transplantation, decreasing mortality due to infections, and increasing progression-free survival. Additionally, the methods include steps for detecting the presence and abundance of specific bacteria in the subject's gastrointestinal tract, as well as monitoring the effects of the composition on various biomarkers and biological activities. Overall, the composition and methods outlined in the patent application aim to address a range of health conditions by leveraging the unique properties of the purified population of bacteria.
To know more about GlobalData’s detailed insights on Seres Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
